# Partial Breast Irradiation for Early-Stage Breast Cancer: Advances, Challenges, and Future Directions—A Narrative Review

## TL;DR

This review discusses the use of partial breast irradiation as a safer and more targeted alternative to whole-breast irradiation for early-stage breast cancer.

## Contribution

The paper synthesizes recent evidence and innovations in PBI to guide future research and clinical practice in precision radiotherapy.

## Key findings

- PBI shows comparable recurrence rates to WBI in well-selected patients.
- MRI-guided radiotherapy and neoadjuvant PBI improve tumor targeting and reduce toxicity.
- Optimizing fractionation and patient selection remains a key challenge for PBI.

## Abstract

Advances in breast cancer treatment have shifted the focus from maximizing local control to balancing oncologic efficacy with treatment de-escalation and toxicity reduction. Whole-breast irradiation (WBI) following breast-conserving surgery remains the standard of care, but with up to 90% of recurrences occurring near the tumor bed, partial breast irradiation (PBI) has emerged as a viable alternative. Large randomized controlled trials (such as IMPORT LOW, Florence, and GEC-ESTRO) have demonstrated comparable ipsilateral breast tumor recurrence (IBTR) rates between PBI and WBI, reinforcing its oncologic safety in well-selected patients. However, challenges remain in optimizing fractionation schedules, refining patient selection, and minimizing late toxicity. Recent innovations, including MRI-guided radiotherapy (MRgRT) and neoadjuvant PBI, offer improved tumor targeting, real-time plan adaptation, and enhanced normal tissue sparing. These advancements hold promise for further reducing radiation-related morbidity and improving cosmetic outcomes. As PBI progresses, integrating novel imaging modalities and hypofractionated regimens will be crucial to refining protocols. This review synthesizes the latest evidence on PBI techniques, clinical outcomes, and emerging technologies to guide future research and clinical decision-making in precision breast radiotherapy.